Adaptimmune Therapeutics, a leader in cell therapy to treat cancer, announced that it has entered into a strategic collaboration and license agreement with Genentech, a member of the Roche Group to develop and commercialize allogeneic cell therapies to treat multiple oncology indications.
The collaboration has two components:
- Development of allogeneic T-cell therapies for up to five shared cancer targets
- Development of personalized allogeneic T-cell therapies
For each component, Adaptimmune will be responsible for developing clinical candidates using its induced pluripotent stem cell (iPSC) derived allogeneic platform to produce T-cells (iT cells). Genentech will be responsible for the input TCRs and subsequent clinical development and commercialization.
Under the terms of the agreement, Adaptimmune will receive an upfront payment of $150 million and additional payments of $150 million over five years, unless the agreement is earlier terminated. In addition, Adaptimmune may be eligible to receive research, development, regulatory and commercial milestones payments potentially exceeding $3 billion in aggregate value.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!